PapersFlow Research Brief
Gout, Hyperuricemia, Uric Acid
Research Guide
What is Gout, Hyperuricemia, Uric Acid?
Gout is an inflammatory arthritis triggered by monosodium urate crystals derived from hyperuricemia, a condition of elevated serum uric acid levels that also associates with cardiovascular and renal diseases.
The field encompasses 52,151 papers on uric acid's roles in gout, hyperuricemia, hypertension, endothelial dysfunction, metabolic syndrome, and renal disease. Uric acid crystals from gout activate the NALP3 inflammasome, driving inflammation via pyroptosis pathways. Xanthine oxidase inhibitors target uric acid production, while studies link hyperuricemia to cardiovascular risk factors.
Topic Hierarchy
Research Sub-Topics
NLRP3 Inflammasome Activation by Uric Acid Crystals
This sub-topic investigates the molecular mechanisms by which monosodium urate crystals trigger NLRP3 inflammasome assembly, caspase-1 activation, and IL-1β release in gout flares. Researchers explore upstream sensors, potassium efflux, and therapeutic targeting of this pathway.
Uric Acid and Cardiovascular Risk Factors
This sub-topic examines the epidemiological and mechanistic links between hyperuricemia, endothelial dysfunction, hypertension, and atherosclerotic cardiovascular disease. Researchers study oxidative stress, xanthine oxidase activity, and urate-lowering therapies' impact on vascular outcomes.
Hyperuricemia in Renal Disease Progression
This sub-topic covers the role of uric acid in chronic kidney disease pathogenesis, including tubulointerstitial damage, glomerular hypertension, and proteinuria. Researchers evaluate allopurinol and febuxostat effects on renal function decline in clinical trials.
Xanthine Oxidase Inhibitors in Gout Management
This sub-topic focuses on pharmacology, efficacy, and safety of xanthine oxidase inhibitors like allopurinol and febuxostat for serum uric acid reduction and gout prevention. Researchers compare dosing regimens, pharmacogenetics, and cardiovascular safety profiles.
Uric Acid and Metabolic Syndrome Pathophysiology
This sub-topic explores uric acid's contributions to insulin resistance, dyslipidemia, visceral adiposity, and metabolic syndrome clustering. Researchers investigate bidirectional relationships with fructose metabolism and adipose tissue inflammation.
Why It Matters
Hyperuricemia and gout impact cardiovascular and renal health, with uric acid implicated as a risk factor for hypertension and chronic kidney disease. Feig et al. (2008) in "Uric Acid and Cardiovascular Risk" reviewed evidence linking elevated uric acid to hypertension, renal disease, and cardiovascular events, though causality remains debated. Martinon et al. (2006) showed in "Gout-associated uric acid crystals activate the NALP3 inflammasome" that urate crystals trigger NALP3 inflammasome activation, explaining gout flares and potential contributions to systemic inflammation. Nidorf et al. (2020) demonstrated in "Colchicine in Patients with Chronic Coronary Disease" that daily 0.5 mg colchicine reduced cardiovascular events in chronic coronary disease patients compared to placebo, highlighting anti-inflammatory treatments' role in managing uric acid-related complications.
Reading Guide
Where to Start
"Gout-associated uric acid crystals activate the NALP3 inflammasome" by Martinon et al. (2006), as it directly establishes the core mechanism linking uric acid crystals to gout inflammation, providing foundational insights with 5122 citations.
Key Papers Explained
Martinon et al. (2006) in "Gout-associated uric acid crystals activate the NALP3 inflammasome" identified urate crystals as specific NALP3 activators. Mariathasan et al. (2006) in "Cryopyrin activates the inflammasome in response to toxins and ATP" expanded on cryopyrin/NLRP3 triggers. He et al. (2016) in "Mechanism and Regulation of NLRP3 Inflammasome Activation" synthesized regulatory pathways. Feig et al. (2008) in "Uric Acid and Cardiovascular Risk" connected hyperuricemia to clinical outcomes. Nidorf et al. (2020) in "Colchicine in Patients with Chronic Coronary Disease" applied these insights to therapy.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize NLRP3 regulation and pyroptosis in uric acid-driven diseases, as detailed in He et al. (2016) "Mechanism and Regulation of NLRP3 Inflammasome Activation" and Yu et al. (2021) "Pyroptosis: mechanisms and diseases". Clinical translation focuses on colchicine's cardiovascular benefits from Nidorf et al. (2020).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Gout-associated uric acid crystals activate the NALP3 inflamma... | 2006 | Nature | 5.1K | ✓ |
| 2 | Pyroptosis: host cell death and inflammation | 2009 | Nature Reviews Microbi... | 3.2K | ✓ |
| 3 | Cryopyrin activates the inflammasome in response to toxins and... | 2006 | Nature | 3.0K | ✓ |
| 4 | Mechanism and Regulation of NLRP3 Inflammasome Activation | 2016 | Trends in Biochemical ... | 2.6K | ✓ |
| 5 | Uric Acid and Cardiovascular Risk | 2008 | New England Journal of... | 2.4K | ✓ |
| 6 | Gasdermin D is an executor of pyroptosis and required for inte... | 2015 | Cell Research | 2.4K | ✓ |
| 7 | The European Spondylarthropathy Study Group Preliminary Criter... | 1991 | Arthritis & Rheumatism | 2.3K | ✕ |
| 8 | Pyroptosis: mechanisms and diseases | 2021 | Signal Transduction an... | 2.1K | ✓ |
| 9 | K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activati... | 2013 | Immunity | 2.0K | ✓ |
| 10 | Colchicine in Patients with Chronic Coronary Disease | 2020 | New England Journal of... | 1.9K | ✓ |
Frequently Asked Questions
What activates the NALP3 inflammasome in gout?
Gout-associated uric acid crystals activate the NALP3 inflammasome. Martinon et al. (2006) demonstrated this in "Gout-associated uric acid crystals activate the NALP3 inflammasome", linking crystal deposition to inflammatory responses in gout.
How does hyperuricemia relate to cardiovascular risk?
Hyperuricemia associates with hypertension, renal disease, and cardiovascular disease. Feig et al. (2008) in "Uric Acid and Cardiovascular Risk" summarized studies debating uric acid as an independent risk factor, presenting evidence from clinical observations.
What is pyroptosis in the context of uric acid inflammation?
Pyroptosis is a lytic inflammatory cell death involving gasdermin D and interleukin-1β secretion. He et al. (2015) showed in "Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion" that it executes NLRP3 inflammasome-driven responses relevant to gout.
How does colchicine benefit patients with cardiovascular disease?
Colchicine reduces cardiovascular events in chronic coronary disease. Nidorf et al. (2020) in a randomized trial in "Colchicine in Patients with Chronic Coronary Disease" found 0.5 mg daily lowered risk compared to placebo.
What triggers NLRP3 inflammasome activation broadly?
K+ efflux commonly triggers NLRP3 inflammasome activation by bacterial toxins and particulates, including uric acid crystals. Muñoz-Planillo et al. (2013) established this in "K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter".
What are key mechanisms regulating NLRP3 inflammasome?
NLRP3 inflammasome activation involves multiple regulatory steps post-priming. He et al. (2016) detailed these in "Mechanism and Regulation of NLRP3 Inflammasome Activation", covering pathways relevant to uric acid crystal responses.
Open Research Questions
- ? Does uric acid act as a causal risk factor for hypertension and cardiovascular disease independent of confounders?
- ? How do xanthine oxidase inhibitors modify gout-related inflammasome activation and systemic inflammation?
- ? What are the precise molecular regulators preventing excessive NLRP3 inflammasome responses to urate crystals?
- ? Can anti-inflammatory agents like colchicine prevent progression from hyperuricemia to renal disease?
- ? How does pyroptosis contribute to endothelial dysfunction in hyperuricemia?
Recent Trends
The field holds steady at 52,151 papers with no reported 5-year growth data.
Highly cited works like Martinon et al. "Gout-associated uric acid crystals activate the NALP3 inflammasome" (5122 citations) and recent applications such as Nidorf et al. (2020) "Colchicine in Patients with Chronic Coronary Disease" (1898 citations) underscore persistent focus on inflammasome mechanisms and anti-inflammatory interventions in hyperuricemia and gout.
2006Research Gout, Hyperuricemia, Uric Acid with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Gout, Hyperuricemia, Uric Acid with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers